Respira
Generic Name
Montelukast
Manufacturer
Acme Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| respira 1 mg tablet | ৳ 0.90 | ৳ 9.00 |
Description
Overview of the medicine
Respira 1 mg Tablet contains Montelukast, a leukotriene receptor antagonist, used for the treatment of asthma and allergic rhinitis. It helps prevent wheezing and shortness of breath caused by asthma, and reduces allergy symptoms like sneezing and runny nose.
Uses & Indications
Dosage
Adults
10 mg tablet once daily in the evening for asthma or allergic rhinitis.
Elderly
No dosage adjustment typically required, but monitor for adverse effects.
Renal_impairment
No dosage adjustment required.
How to Take
Respira 1 mg tablet should be taken orally once daily in the evening, with or without food. For asthma, it should be taken in the evening. For allergic rhinitis, the time of administration may be individualized to suit patient needs. Do not chew or crush the tablet unless it is a chewable formulation.
Mechanism of Action
Montelukast selectively antagonizes the cysteinyl leukotriene 1 (CysLT1) receptor. Leukotrienes are potent inflammatory mediators released from various cells, which contribute to the pathophysiology of asthma and allergic rhinitis, including bronchoconstriction, mucous secretion, vascular permeability, and eosinophil recruitment. By blocking the action of leukotrienes, Montelukast reduces these inflammatory responses.
Pharmacokinetics
Onset
Clinical improvement typically seen within 1 day (24 hours) of starting treatment.
Excretion
Primarily excreted in the feces via bile (approximately 86%), with minimal excretion in the urine (less than 0.2%).
Half life
Approximately 2.7 to 5.5 hours in healthy young adults.
Absorption
Rapidly absorbed from the gastrointestinal tract following oral administration. Peak plasma concentrations are achieved in approximately 2-4 hours.
Metabolism
Extensively metabolized in the liver by cytochrome P450 enzymes, primarily CYP2C8 and CYP3A4, with minor contribution from CYP2C9.
Side Effects
Contraindications
- Hypersensitivity to Montelukast or any component of the tablet.
Drug Interactions
Rifampicin
May decrease plasma concentrations of Montelukast, potentially reducing its efficacy.
Phenobarbital
May decrease the area under the curve (AUC) of Montelukast, requiring careful monitoring.
Storage
Store in a cool, dry place, below 30°C. Protect from light and moisture. Keep out of reach of children.
Overdose
In cases of overdose, supportive and symptomatic treatment should be provided. There is no specific antidote.
Pregnancy & Lactation
Pregnancy Category B. Montelukast should be used during pregnancy only if clearly needed. It is unknown whether Montelukast is excreted in human milk; use with caution in nursing mothers.
Side Effects
Contraindications
- Hypersensitivity to Montelukast or any component of the tablet.
Drug Interactions
Rifampicin
May decrease plasma concentrations of Montelukast, potentially reducing its efficacy.
Phenobarbital
May decrease the area under the curve (AUC) of Montelukast, requiring careful monitoring.
Storage
Store in a cool, dry place, below 30°C. Protect from light and moisture. Keep out of reach of children.
Overdose
In cases of overdose, supportive and symptomatic treatment should be provided. There is no specific antidote.
Pregnancy & Lactation
Pregnancy Category B. Montelukast should be used during pregnancy only if clearly needed. It is unknown whether Montelukast is excreted in human milk; use with caution in nursing mothers.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 to 36 months from the date of manufacture, depending on storage conditions.
Availability
Pharmacies nationwide
Approval Status
Approved by DGDA
Patent Status
Generic available
WHO Essential Medicine
YesClinical Trials
Extensive clinical trials have demonstrated Montelukast's efficacy and safety in the treatment of asthma and allergic rhinitis across various age groups. Post-marketing surveillance continues to monitor for rare adverse events.
Lab Monitoring
- No specific routine laboratory monitoring is required for Montelukast. Liver function tests may be considered in patients with pre-existing liver impairment.
Doctor Notes
- Counsel patients and caregivers on the potential for neuropsychiatric events and the importance of reporting any changes.
- Montelukast is a prophylactic agent and should not be used for acute bronchospasm. Advise patients to carry their rescue inhaler.
- Consider alternative therapies if patients develop significant neuropsychiatric symptoms.
Patient Guidelines
- Take this medicine exactly as prescribed by your doctor.
- Do not stop taking Respira even if you feel better, without consulting your doctor.
- Report any changes in mood or behavior, including depression or suicidal thoughts, to your doctor immediately.
- Respira is not for use in acute asthma attacks; use a fast-acting inhaler for such attacks.
Missed Dose Advice
If a dose is missed, take the next dose at the usual time. Do not take a double dose to make up for a missed one. Continue with the regular dosing schedule.
Driving Precautions
Some patients may experience dizziness or drowsiness. Patients should be cautious when driving or operating machinery until they know how Montelukast affects them.
Lifestyle Advice
- Identify and avoid asthma and allergy triggers.
- Maintain a healthy lifestyle, including regular exercise (if appropriate) and a balanced diet.
- Regularly follow up with your doctor to manage your asthma/allergy.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Respira Brand
Other medicines available under the same brand name
